US20050158250A1 - Composition of insulin for nasal administration - Google Patents

Composition of insulin for nasal administration Download PDF

Info

Publication number
US20050158250A1
US20050158250A1 US11/078,292 US7829205A US2005158250A1 US 20050158250 A1 US20050158250 A1 US 20050158250A1 US 7829205 A US7829205 A US 7829205A US 2005158250 A1 US2005158250 A1 US 2005158250A1
Authority
US
United States
Prior art keywords
insulin
avicel
crystalline cellulose
administration
hrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/078,292
Inventor
Toshikazu Oki
Takashi Hanafusa
Shunji Haruta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/078,292 priority Critical patent/US20050158250A1/en
Publication of US20050158250A1 publication Critical patent/US20050158250A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • the present invention relates to a pharmaceutical formulation, the distinguishing features of which are that it is granular in form and is administered via the nasal mucosa. Specifically, the present invention relates to a granulated composition of insulin for nasal administration as a therapeutic treatment for diabetes.
  • the insulin used in the clinical treatment of diabetes is in the form of an injectable formulation, and in most cases is self-administered by a comparatively simple subcutaneous injection.
  • the characteristics of this type of drug are such that the patient must self-administer before meals, once to four times a day for life. This troublesome procedure is only one of the many problems associated with the treatment of diabetes.
  • JP-1059841-A (corresponding to EP-943326-A1) with regard to high hydrophilic drugs, high lipophilic drugs and peptides with high molecular weight, describes an excellent example of compositions with superior nasal absorption and increased maximum blood concentrations. According to this official gazette, this action effect can be positively achieved using a water-absorbing and basic gel-forming base such as hydroxypropylcellulose in combination with aggregate crystalline cellulose of particle diameter greater than 150 ⁇ m on the contrary to JP-6242888-B suggesting that a relatively small particle diameter of 20-150 ⁇ m is preferred as the preparation.
  • a water-absorbing and basic gel-forming base such as hydroxypropylcellulose in combination with aggregate crystalline cellulose of particle diameter greater than 150 ⁇ m
  • the present inventors have found a nasal composition that unlike those described in the foregoing JP-6242888-B and JP-1059841-A uses non-solubilized powdered insulin and a special, aggregate crystalline cellulose with a particle diameter of less than 150 ⁇ m, which in comparison with existing compositions, significantly increases insulin absorption enabling enhanced therapeutic efficacy in the treatment of diabetes patients.
  • the present invention is based on this knowledge.
  • the present invention relates to powdered insulin composition for nasal administration that composed of powdered insulin and its carrier, aggregated crystalline cellulose, the distinguishing features of which are that the said insulin is non-solubilized, and 90 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 10-350 ⁇ m in one part or across the whole particle area.
  • the present invention relates to powdered insulin composition for nasal administration that composed of powdered insulin and its carrier, aggregated crystalline cellulose, the distinguishing features of which are that the said insulin is not only non-solubilized but solubilized, and 85 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 20-60 ⁇ m in one part or across the whole area.
  • Another mode of the present invention relates to use of a crystalline cellulose aggregate as a carrier for preparing a granulated composition for nasal absorption, containing insulin, for the treatment of diabetes (in which 90 w/w % or more of the particles in the said aggregated crystalline cellulose has a cribriform particle diameter range of 10-350 ⁇ m in one part or across the whole area).
  • a further mode of the present invention relates to a therapeutic method for diabetes, spraying a granulated composition composed of powdered insulin and its carrier, aggregated crystalline cellulose (the distinguishing features of which are that the said insulin is non-solubilized, and 90 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 10-350 ⁇ m in one part or across the whole area) into the nasal cavity of diabetic patients at sufficient insulin doses for an effective diabetic treatment.
  • FIG. 1 is a graph showing changes in serum insulin concentrations after intranasal administration of each preparation in cynomolgus monkeys.
  • - ⁇ - a preparation with Avicel® PH-F20
  • - ⁇ - a preparation with Avicel® PH-F20 (solubilized insulin)
  • - ⁇ - a preparation with Avicel® PH-101
  • -*- a preparation with Avicel® PH-101 (solubilized insulin).
  • FIG. 2 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys. The legends correspond to those in FIG. 1 .
  • FIG. 3 is a graph showing changes in serum insulin concentrations after intranasal administration of each preparation in cynomolgus monkeys.
  • - ⁇ - a preparation with Avicel® PH-101
  • - ⁇ - a preparation with Avicel® PH-301
  • - ⁇ - a preparation with Avicel® PH-F20
  • -*- a preparation with Avicel® PH-M15.
  • FIG. 4 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys. The legends correspond to those in FIG. 3 .
  • FIG. 5 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys.
  • - ⁇ - a preparation with Avicel® PH-F20;
  • - ⁇ - a preparation with Avicel® PH-F20 (20-25 ⁇ m);
  • - ⁇ - a preparation with Avicel® PH-F20 (25-38 ⁇ m);
  • - ⁇ - a preparation with Avicel® PH-F20 (38-53 ⁇ m);
  • -*- a preparation with Avicel® PH-F20 (25-53 ⁇ m);
  • - ⁇ - a preparation with Avicel® PH-F20 ( ⁇ 53 ⁇ m);
  • - ⁇ - a preparation with Avicel® PH-F20 (>53 ⁇ m).
  • FIG. 6 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys. The legends correspond to those in FIG. 5 .
  • FIG. 7 is a graph showing changes in serum insulin concentrations after intranasal administration of a preparation with Avicel® PH-F20 as a carrier in humans.
  • FIG. 8 is a graph showing changes in serum glucose concentrations after intranasal administration of a preparation with Avicel® PH-F20 as a carrier in humans.
  • Insulin any form of modified or unmodified insulin used in treating diabetes in humans can be used with the present invention, regardless of its origin. Accordingly, the term ‘Insulin’ as used here is deemed to mean all types in current or future clinical use, having the same physiologically activity as that of human insulin including human insulin, refined bovine insulin, refined porcine insulin, semi-synthesized human insulin, human isoinsulin, genetically modified human insulin or its variants thereof.
  • Powder forms of these types of insulin or insulin that is only slightly soluble in water or almost insoluble in water can also be preferably used with the present invention.
  • solubilized powdered insulin including insulin other than the described above ‘non-solubilized’ powdered insulin, is typically understood to be a substance that has itself become solubilized by means of the known method of treatment described in JP-6242888-B.
  • solubilized insulin can be obtained by freeze-drying after producing an acidified aqueous insulin solution by means of a specific surfactant.
  • Insulin powder as described above can be of a finely powdered crystalline or non-crystalline structure, finer in comparison with the particulate cellulose described later, which composes aggregated crystalline cellulose. Generally, these multiple powders adhere to the surface of particulate cellulose or to the surface of microstructures (E.g. pores), or can also be of an encapsulating size. Generally, the various forms of insulin marketed in the form of medicinal powder can be used without alteration.
  • aggregated crystalline cellulose as used in the present invention is refined from the water-insoluble part of ⁇ -cellulose that is obtained as a pulp from plant fiber and partially de-polymerized with acid. It is possible to use aggregated crystalline cellulose obtained from rayon fiber etc. provided that it meets the purpose of the present invention.
  • the size of that derived from Avicel®, or a variant thereof, as described in JP-3912469-B, JP-5638128-B, JP-6121201-B, and JP-0538732-B can if necessary, be reduced by processing with a high-speed impact or air flow-type pulverizer, and/or the bulk density increased by fine pulverization, after which aggregated crystalline cellulose of required particle aggregate size can be obtained by classification or sifting for use with the present invention.
  • This kind of aggregated crystalline cellulose can usually be produced by de-polymerization as described above and there is no limit to its mean degree of polymerization provided that it meets the purpose of the present invention. Generally, however, crystalline cellulose having a mean polymerization degree between 15 and 400, more preferably 20 and 250, or ideally 30 and 50 can be selected. Although there is no restriction on the aggregated crystalline cellulose that can be utilized, that with a bulk density of 0.20-0.65 g/cm 3 is preferable and, 0.22-0.40 g/cm 3 is ideal. These bulk density values accord to measurement by the Scott Volumeter.
  • the principal factors demanded for aggregated crystalline cellulose that can be used with the present invention are the size and distributive pattern of the crystalline cellulose particles that constitute the aggregate. When expressed as the cribriform particle diameter range, particles should occupy a range of 10-350 ⁇ m partially, or 90 w/w % and above in their entirety.
  • a part or whole area can, be defined as, conforming to the particle size distribution as shown; for example, in Avicel® PH-101 or PH-301, in which 90 w/w % or more of the particles are distributed, for example, over a range of 10-150 ⁇ m as part of a diameter of 10-350 ⁇ m, or in which 90 w/w % or more of the particles are distributed over a whole area of 10-350 ⁇ m.
  • These ranges, extending over a whole area of 10-150 ⁇ m, or a part thereof are acceptable if they comply to the present invention.
  • Crystalline cellulose such as this can be obtained from the FMC Corporation of the United States and the Asahi Chemical Industrial Co., Ltd. as Avicel® PH-101, PH-301, and PH-M15 and may be used in the base form or obtained by grading.
  • Avicel® PH-F20 or PH-M15 can be graded or used as commercially available.
  • crystalline cellulose aggregate having a particle diameter is used jointly with water absorbent and gel-forming base materials in JP-1059841-A (or, EP-943326-A1), the use crystalline cellulose having particle diameters of 38-250 ⁇ m is shown as preferred mode, and the use of crystalline cellulose having a particle diameter of 100-250 ⁇ m is shown as the practical example.
  • Particularly preferred more specific crystalline cellulose which can achieve such actions and effects include, includes but not limited to one having a particle distribution of:
  • the mixing ratio of powdered insulin and the aggregated crystalline cellulose is adjusted to 1:1-500 w/w, and more preferably 1:2-100.
  • Composition that accord to the present invention can be prepared by homogenizing the above-mentioned powdered insulin and aggregated crystalline cellulose by a standard (for example, a blender, a mixer).
  • a standard for example, a blender, a mixer.
  • the ambient conditions can be controlled, relative humidity should not exceed 60% and ideally should be below 40% at room temperature. Subsequently, if required, particles of less than 10 ⁇ m may be removed; however, the inventor needed no removal operations on the basis of their experience.
  • compositions in a different form that accord to the present invention are, in addition to the above-mentioned compositions, acceptable provided that they do not exert any effect contrary to the purpose of the present invention, and this includes other carriers or base materials, excipients, preservatives, antiseptics, and absorption accelerants.
  • other carriers might include cellulose conductors such as hydroxypropylcellulose, hydroxypropylmethylcellulose, or methylcellulose as described in JP-1059841-A. When other carrier or diluting agents, are used in this manner, it is desirable that the compositions obtained be cribrated.
  • the particle diameter or particle distribution of the granulated composition obtained is substantially the same as that of the aggregated crystalline cellulose used.
  • the particle diameter of the granulated composition significantly exceeds that of the aggregated crystalline cellulose, it is desirable that the composition be sifted to obtain the specified particle diameter.
  • the term ‘substantially the same’ as used in this specification shall be taken to mean a maximum difference in comparison with the control diameter of 10% and ideally, no greater than 5%.
  • composition of the nasally administered insulin thus obtained for the present invention can, when compared to conventional compositions, achieve remarkably high insulin absorption.
  • the granulated composition of the present invention enables the treatment of diabetes by nasal administration to patients.
  • Nasal administration of such granulated composition is possible using any device capable of efficient delivery via the nasal mucosa, and devices already on the market (e.g. Jetlizer, Unisia Jecs Corporation.) may be used as they are.
  • the maximum or most appropriate dose to be administered to diabetes patients will vary according to individual cases and the severity of the condition, and can not therefore be readily prescribed.
  • a medical specialist can, in consideration of serum insulin and glucose concentrations and efficacy following normal subcutaneous injection, determine the appropriate dosage in reference to the results of administration to both cynomolgus monkeys and healthy adult humans shown below.
  • the present invention also relates to a therapeutic method for diabetes using the granulated insulin composition mentioned above.
  • the present invention shall further be explained details of nasal delivery of granulated insulin according to the present invention and specific comparative examples, but it is not intended that the present invention be restricted to these.
  • the insulin used in these examples was recombinant human insulin supplied by Intergene Co., Ltd.
  • Insulin and glucose concentrations were measured by Enzyme Immune Assay (EIA) and Glck•G-6-PDH, respectively.
  • Each pharmaceutical preparation was placed in a capsule, and administered intranasally with an administration device (Jetlizer, Unisia Jecs Corporation).
  • Table 1 shows that when 16 IU/head of insulin was nasally administered, the most favorable insulin absorption was seen in the order water-insoluble insulin with Avicel® PH-F20, followed by water-soluble insulin with Avicel® PH-F20, water-insoluble insulin with Avicel® PH-101 (all these are the present invention), water-soluble insulin with Avicel® PH-101 (comparison), and it is clear that the compositions according to the present invention reached significantly high serum insulin concentrations in comparison with the comparative composition.
  • FIGS. 3 and 4 Serum insulin and glucose concentration-time curves after nasal administration of compositions described above are shown in FIGS. 3 and 4 .
  • Raw data relating to FIG. 3 are shown in Tables 7 to 10.
  • TABLE 6 Kind of Dosage Number of AUC 0-4 preparation (IU/body) animals C max ( ⁇ U/mL) T max (h) T 1/2 (h) ( ⁇ U ⁇ h/mL) AVICEL PH-101 16 6 164.73 ⁇ 70.76 0.33 ⁇ 0.10 0.78 ⁇ 0.26 129.78 ⁇ 78.45 AVICEL PH-301 16 6 353.57 ⁇ 174.91 0.39 ⁇ 0.14 0.65 ⁇ 0.10 328.13 ⁇ 162.93 AVICEL PH-F20 16 6 449.35 ⁇ 183.66 0.33 ⁇ 0.10 0.75 ⁇ 0.33 361.55 ⁇ 167.55 AVICEL PH-M15 16 6 225.40 ⁇ 89.70 0.28
  • Table 6 shows that when 16 IU/head of insulin was nasally administered, the most favorable insulin absorption was seen in the order Avicel® PH-F20, followed by Avicel® 301, Avicel® PH-M15, and Avicel® PH-101 in that order, and it is clear that the compositions according to the present invention reached significantly high serum insulin concentrations in comparison with the comparative composition.
  • AUC 0-4 ( ⁇ U ⁇ h/mL) of Avicel® PH-F20 was about three times that of Avicel® PH-101 (see FIG. 3 ).
  • Avicel® PH-101 and Avicel® PH-F20 were produced serially; Avicel® PH-101 being chopped and pulverized to form Avicel® PH-F20.
  • the method of producing Avicel® 301 and Avicel® PH-M15 was different from that of Avicel® PH-101.
  • Avicel® PH-F20, Avicel® 301, Avicel® PH-M15, and Avicel® PH-101 have bulk densities of 0.23, 0.39, 0.53, and 0.29 g/cm 3 , respectively.
  • FIGS. 5 and 6 Serum insulin and glucose concentration-time curves after nasal administration of preparations described above are shown in FIGS. 5 and 6 .
  • Raw data relating to FIG. 5 are shown in Tables 13-19.
  • TABLE 13 Administration of F20 (chronological change in insulin concentration) Animal Insulin ( ⁇ U/mL) No.
  • Table 12 shows that when 16 IU/head of insulin was nasally administered, insulin absorption with unclassified F-20 particles and aggregated crystalline cellulose preparations with a particle distribution across a partial region of the diameter range was slightly lower than the maximum serum insulin concentration of F-20; however, it was significantly higher than that of the comparative composition.
  • Table 20 shows that the raw data of intravenous administration of insulin injection solution are shown in Table 20. TABLE 20 Intravenous administration (chronological change in insulin concentration) Animal Insulin ( ⁇ U/mL) No.
  • a composition with Avicel® PH-F20 as the carrier was nasally administered once and serum insulin and glucose concentrations were measured chronologically.
  • Insulin and glucose concentrations were measured by Enzyme Immune Assay (EIA) and Glck•G-6-PDH, respectively.
  • Each pharmaceutical preparation was placed in a capsule, and administered intranasally with an administration device (Jetlizer, Unisia Jecs Corporation).
  • Table 21 shows that granulated compositions related to the present invention show favorable serum insulin concentrations and are excellent nasal administration agents (refer to FIGS. 7 and 8 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided is an insulin-containing granulated composition for nasal administration comprising a crystalline cellulose aggregate having a specific particle diameter distribution as a carrier. Such granulated composition for nasal administration can efficiently increase a blood insulin concentration.

Description

    TECHNICAL FIELD
  • The present invention relates to a pharmaceutical formulation, the distinguishing features of which are that it is granular in form and is administered via the nasal mucosa. Specifically, the present invention relates to a granulated composition of insulin for nasal administration as a therapeutic treatment for diabetes.
    • BACKGROUND ART
  • At present, the insulin used in the clinical treatment of diabetes is in the form of an injectable formulation, and in most cases is self-administered by a comparatively simple subcutaneous injection. The characteristics of this type of drug are such that the patient must self-administer before meals, once to four times a day for life. This troublesome procedure is only one of the many problems associated with the treatment of diabetes.
  • Preparations for nasal administration have been proposed as a remedy to the difficulties associated with subcutaneous administration. For example, an insulin formulation in which 90 w/w % of the particle diameters ranged from 20-150 μm, using crystalline cellulose as a basic material was described in JP-6242888-B. Under the suggestion that ‘Physiological polypeptides for nasal mucosal absorption are preferably water-soluble’ in this preparation, the practical example described in the said publication show a formulation in which 90 w/w % or more of the particle diameters ranged from 75-149 μm can be obtained after dissolving insulin in 0.1N HCl, freeze-drying, mixing the soluble insulin thus obtained with crystalline cellulose, and sifting.
  • In comparison with the above-mentioned JP-6242888-B, JP-1059841-A (corresponding to EP-943326-A1) with regard to high hydrophilic drugs, high lipophilic drugs and peptides with high molecular weight, describes an excellent example of compositions with superior nasal absorption and increased maximum blood concentrations. According to this official gazette, this action effect can be positively achieved using a water-absorbing and basic gel-forming base such as hydroxypropylcellulose in combination with aggregate crystalline cellulose of particle diameter greater than 150 μm on the contrary to JP-6242888-B suggesting that a relatively small particle diameter of 20-150 μm is preferred as the preparation.
  • However, the present inventors have no information on the practical application of insulin formulations for nasal administration including these related prior arts. A composition that will enable nasal administration of insulin for practical use and particularly markedly increased nasal insulin absorption, is, therefore, still needed.
    • DISCLOSURE OF THE INVENTION
  • The present inventors have found a nasal composition that unlike those described in the foregoing JP-6242888-B and JP-1059841-A uses non-solubilized powdered insulin and a special, aggregate crystalline cellulose with a particle diameter of less than 150 μm, which in comparison with existing compositions, significantly increases insulin absorption enabling enhanced therapeutic efficacy in the treatment of diabetes patients.
  • The present invention is based on this knowledge.
  • Accordingly, the present invention relates to powdered insulin composition for nasal administration that composed of powdered insulin and its carrier, aggregated crystalline cellulose, the distinguishing features of which are that the said insulin is non-solubilized, and 90 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 10-350 μm in one part or across the whole particle area.
  • Moreover, the present invention relates to powdered insulin composition for nasal administration that composed of powdered insulin and its carrier, aggregated crystalline cellulose, the distinguishing features of which are that the said insulin is not only non-solubilized but solubilized, and 85 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 20-60 μm in one part or across the whole area.
  • Another mode of the present invention relates to use of a crystalline cellulose aggregate as a carrier for preparing a granulated composition for nasal absorption, containing insulin, for the treatment of diabetes (in which 90 w/w % or more of the particles in the said aggregated crystalline cellulose has a cribriform particle diameter range of 10-350 μm in one part or across the whole area).
  • A further mode of the present invention relates to a therapeutic method for diabetes, spraying a granulated composition composed of powdered insulin and its carrier, aggregated crystalline cellulose (the distinguishing features of which are that the said insulin is non-solubilized, and 90 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 10-350 μm in one part or across the whole area) into the nasal cavity of diabetic patients at sufficient insulin doses for an effective diabetic treatment.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 is a graph showing changes in serum insulin concentrations after intranasal administration of each preparation in cynomolgus monkeys. -♦-, a preparation with Avicel® PH-F20; -▪-, a preparation with Avicel® PH-F20 (solubilized insulin); -Δ-, a preparation with Avicel® PH-101; -*-, a preparation with Avicel® PH-101 (solubilized insulin).
  • FIG. 2 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys. The legends correspond to those in FIG. 1.
  • FIG. 3 is a graph showing changes in serum insulin concentrations after intranasal administration of each preparation in cynomolgus monkeys. -♦-, a preparation with Avicel® PH-101; -▪-, a preparation with Avicel® PH-301; -Δ-, a preparation with Avicel® PH-F20; -*-, a preparation with Avicel® PH-M15.
  • FIG. 4 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys. The legends correspond to those in FIG. 3.
  • FIG. 5 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys. -♦-, a preparation with Avicel® PH-F20; -▪-, a preparation with Avicel® PH-F20 (20-25 μm); -Δ-, a preparation with Avicel® PH-F20 (25-38 μm); -×-, a preparation with Avicel® PH-F20 (38-53 μm); -*-, a preparation with Avicel® PH-F20 (25-53 μm); -●-, a preparation with Avicel® PH-F20 (<53 μm); -⊥-, a preparation with Avicel® PH-F20 (>53 μm).
  • FIG. 6 is a graph showing changes in serum glucose concentrations after intranasal administration of each preparation in cynomolgus monkeys. The legends correspond to those in FIG. 5.
  • FIG. 7 is a graph showing changes in serum insulin concentrations after intranasal administration of a preparation with Avicel® PH-F20 as a carrier in humans.
  • FIG. 8 is a graph showing changes in serum glucose concentrations after intranasal administration of a preparation with Avicel® PH-F20 as a carrier in humans.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • Any form of modified or unmodified insulin used in treating diabetes in humans can be used with the present invention, regardless of its origin. Accordingly, the term ‘Insulin’ as used here is deemed to mean all types in current or future clinical use, having the same physiologically activity as that of human insulin including human insulin, refined bovine insulin, refined porcine insulin, semi-synthesized human insulin, human isoinsulin, genetically modified human insulin or its variants thereof. Powder forms of these types of insulin or insulin that is only slightly soluble in water or almost insoluble in water (Corresponding to 1 g of powdered insulin requiring solvent in excess of 1000 mL and less than 10000 mL, or in excess of 10000 mL; see 13th Japan Pharmacopoeia, Principles of Operation A-51) even if modified, can also be preferably used with the present invention.
  • Given that the type of insulin described previously is slightly soluble in water or almost insoluble in water, insulin used with the present invention can be described as ‘non-solubilized’ powdered insulin. With regard to this, solubilized powdered insulin, including insulin other than the described above ‘non-solubilized’ powdered insulin, is typically understood to be a substance that has itself become solubilized by means of the known method of treatment described in JP-6242888-B. In general terms, solubilized insulin can be obtained by freeze-drying after producing an acidified aqueous insulin solution by means of a specific surfactant.
  • Insulin powder as described above can be of a finely powdered crystalline or non-crystalline structure, finer in comparison with the particulate cellulose described later, which composes aggregated crystalline cellulose. Generally, these multiple powders adhere to the surface of particulate cellulose or to the surface of microstructures (E.g. pores), or can also be of an encapsulating size. Generally, the various forms of insulin marketed in the form of medicinal powder can be used without alteration.
  • Generally, ‘aggregated crystalline cellulose’ as used in the present invention is refined from the water-insoluble part of α-cellulose that is obtained as a pulp from plant fiber and partially de-polymerized with acid. It is possible to use aggregated crystalline cellulose obtained from rayon fiber etc. provided that it meets the purpose of the present invention. Moreover, the size of that derived from Avicel®, or a variant thereof, as described in JP-3912469-B, JP-5638128-B, JP-6121201-B, and JP-0538732-B, can if necessary, be reduced by processing with a high-speed impact or air flow-type pulverizer, and/or the bulk density increased by fine pulverization, after which aggregated crystalline cellulose of required particle aggregate size can be obtained by classification or sifting for use with the present invention.
  • This kind of aggregated crystalline cellulose can usually be produced by de-polymerization as described above and there is no limit to its mean degree of polymerization provided that it meets the purpose of the present invention. Generally, however, crystalline cellulose having a mean polymerization degree between 15 and 400, more preferably 20 and 250, or ideally 30 and 50 can be selected. Although there is no restriction on the aggregated crystalline cellulose that can be utilized, that with a bulk density of 0.20-0.65 g/cm3 is preferable and, 0.22-0.40 g/cm3 is ideal. These bulk density values accord to measurement by the Scott Volumeter.
  • The principal factors demanded for aggregated crystalline cellulose that can be used with the present invention are the size and distributive pattern of the crystalline cellulose particles that constitute the aggregate. When expressed as the cribriform particle diameter range, particles should occupy a range of 10-350 μm partially, or 90 w/w % and above in their entirety.
  • Subsequent reference to particle size in this statement shall be taken to mean ‘cribriform particle diameter’, obtained from repeated sifting with standard screens, equal to the arithmetic or geometric mean of such screens unless otherwise stated.
  • This kind of aggregate, particularly in combination with non-solubilized insulin powder can be used. ‘A part or whole area’ can, be defined as, conforming to the particle size distribution as shown; for example, in Avicel® PH-101 or PH-301, in which 90 w/w % or more of the particles are distributed, for example, over a range of 10-150 μm as part of a diameter of 10-350 μm, or in which 90 w/w % or more of the particles are distributed over a whole area of 10-350 μm. These ranges, extending over a whole area of 10-150 μm, or a part thereof are acceptable if they comply to the present invention. Crystalline cellulose such as this can be obtained from the FMC Corporation of the United States and the Asahi Chemical Industrial Co., Ltd. as Avicel® PH-101, PH-301, and PH-M15 and may be used in the base form or obtained by grading.
  • A particle range extending over a whole area of 20-60 μm, or part thereof; for example, aggregated crystalline cellulose in which approximately 85 w/w % or more of the particles are distributed over 20—approximately 40 μm, 20—approximately 55 μm, approximately 25—approximately 38 μm, approximately 25—approximately 53 μm or approximately 38 —approximately 53 μm is more preferable. Specifically, Avicel® PH-F20 or PH-M15 can be graded or used as commercially available. While crystalline cellulose aggregate having a particle diameter is used jointly with water absorbent and gel-forming base materials in JP-1059841-A (or, EP-943326-A1), the use crystalline cellulose having particle diameters of 38-250 μm is shown as preferred mode, and the use of crystalline cellulose having a particle diameter of 100-250 μm is shown as the practical example. In the present invention, when using aggregated crystalline cellulose within more preferable particle diameter ranges as the described above, even when used only crystalline cellulose as carriers, a remarkable feature is the ability to achieve significantly higher insulin absorption after nasal administration of solubilized or non-solubilized insulin in comparison with the prior arts (even if it is not used jointly with water absorbent and gel-forming base materials in JP-1059841-A.).
  • Particularly preferred more specific crystalline cellulose, which can achieve such actions and effects include, includes but not limited to one having a particle distribution of:
    • 10 w/w % or less of particle diameters below 25 μm,
    • 20-60 w/w % of particle diameters of 25-38 μm,
    • 20-60 w/w % of particle diameters greater than 38 μm and up to 53 μm, and
    • 10 w/w % or less of particle diameters exceeding 53 μm, taking the entire particle as 100%.
  • Particularly favored are such aggregated crystalline cellulose that substantially do not contain particle diameters below 10 μm. The term ‘substantially do not contain’ as used in the present specification or invention shall be taken to mean no particle or present only a small percentage.
  • When according to the present invention, the mixing ratio of powdered insulin and the aggregated crystalline cellulose is adjusted to 1:1-500 w/w, and more preferably 1:2-100.
  • Composition that accord to the present invention can be prepared by homogenizing the above-mentioned powdered insulin and aggregated crystalline cellulose by a standard (for example, a blender, a mixer). The ambient conditions can be controlled, relative humidity should not exceed 60% and ideally should be below 40% at room temperature. Subsequently, if required, particles of less than 10 μm may be removed; however, the inventor needed no removal operations on the basis of their experience.
  • Compositions in a different form that accord to the present invention are, in addition to the above-mentioned compositions, acceptable provided that they do not exert any effect contrary to the purpose of the present invention, and this includes other carriers or base materials, excipients, preservatives, antiseptics, and absorption accelerants. For example, other carriers might include cellulose conductors such as hydroxypropylcellulose, hydroxypropylmethylcellulose, or methylcellulose as described in JP-1059841-A. When other carrier or diluting agents, are used in this manner, it is desirable that the compositions obtained be cribrated.
  • According to the method of preparation of the present invention, when the proportions of powdered insulin and aggregated crystalline cellulose used, particularly the insulin proportion, are not particularly high (e.g. 1/50 and above) or when excipients as mentioned above are not used, the particle diameter or particle distribution of the granulated composition obtained is substantially the same as that of the aggregated crystalline cellulose used. However if the particle diameter of the granulated composition significantly exceeds that of the aggregated crystalline cellulose, it is desirable that the composition be sifted to obtain the specified particle diameter. The term ‘substantially the same’ as used in this specification shall be taken to mean a maximum difference in comparison with the control diameter of 10% and ideally, no greater than 5%.
  • The composition of the nasally administered insulin thus obtained for the present invention can, when compared to conventional compositions, achieve remarkably high insulin absorption.
  • Accordingly, the granulated composition of the present invention enables the treatment of diabetes by nasal administration to patients. Nasal administration of such granulated composition is possible using any device capable of efficient delivery via the nasal mucosa, and devices already on the market (e.g. Jetlizer, Unisia Jecs Corporation.) may be used as they are.
  • The maximum or most appropriate dose to be administered to diabetes patients will vary according to individual cases and the severity of the condition, and can not therefore be readily prescribed. However, a medical specialist can, in consideration of serum insulin and glucose concentrations and efficacy following normal subcutaneous injection, determine the appropriate dosage in reference to the results of administration to both cynomolgus monkeys and healthy adult humans shown below.
  • Accordingly, the present invention also relates to a therapeutic method for diabetes using the granulated insulin composition mentioned above.
  • The present invention shall further be explained details of nasal delivery of granulated insulin according to the present invention and specific comparative examples, but it is not intended that the present invention be restricted to these. The insulin used in these examples was recombinant human insulin supplied by Intergene Co., Ltd.
  • Pharmacokinetic and Pharmacological Studies in Cynomolgus Monkeys
  • Unless specified, six male monkeys (body weight: 3-7 kg) in each study group were nasally administered once and serum insulin and glucose concentrations were measured chronologically.
  • Insulin and glucose concentrations were measured by Enzyme Immune Assay (EIA) and Glck•G-6-PDH, respectively.
  • Each pharmaceutical preparation was placed in a capsule, and administered intranasally with an administration device (Jetlizer, Unisia Jecs Corporation).
  • (1) 35 mg of powdered water-insoluble insulin (28.7 IU/mg), received as described above, and crystalline cellulose compositions [Asahi Chemical Industrial Co., Ltd.: Avicel® PH-101 and Avicel® PH-F20 (965 mg of each)], were thoroughly mixed in a mortar to prepare nasal administration compositions. 100 mg of powdered water-insoluble insulin was then dissolved in 1 mL of 0.1 N-hydrochloric acid, and water-soluble insulin was prepared by adding 40 mL of purified water to the insulin solution and freeze-drying. 36 mg of powdered, water-soluble insulin (27.7 IU/mg) obtained by this procedure and 964 mg of the above-mentioned crystalline cellulose were thoroughly mixed, and the composition for nasal administration was administered to cynomolgus monkeys (n=6). Pharmacokinetic parameters calculated from serum insulin concentrations after administration are shown in Table 1 (mean value±SD).
  • Serum insulin concentration and glucose concentration-time curves of each nasal absorption formulation stated above are shown in Tables 1 and 2, respectively. Raw data regarding Table 1 are shown in Tables 2 to 5.
    TABLE 1
    Dosage Number of AUC0-4
    Kind of preparation (IU/body) animals Cmax (μU/mL) Tmax (h) T1/2 (h) (μU · h/mL)
    Present AVICEL PH-F20 16 6 449.35 ± 183.66 0.33 ± 0.10 0.75 ± 0.33 361.55 ± 167.55
    invention (water-insoluble insulin)
    AVICEL PH-F20 16 6 176.45 ± 143.46 0.28 ± 0.13 0.86 ± 0.44 157.33 ± 138.12
    (water-soluble insulin)
    AVICEL PH-101 16 6 164.73 ± 70.76 0.33 ± 0.10 0.78 ± 0.26 129.78 ± 78.45
    (water-insoluble insulin)
    Comparison AVICEL PH-101 16 6 153.95 ± 31.96 0.20 ± 0.07 0.96 ± 0.79 102.88 ± 24.16
    (water-soluble insulin)

    Remarks:

    Cmax: maximum blood concentration of insulin

    Tmax: time to reach maximum blood concentration

    T1/2: time for maximum blood concentration to decrease by half

    AUC0-4: whole area under the blood concentration curve from 0-4 hours
  • TABLE 2
    Administration of AVICEL PH-F20 (water-insoluble insulin)
    (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 60.8 225.2 239.6 194.6 149.8 66.9 10.0 2.3
    2 24.1 349.0 632.0 529.5 412.5 181.2 45.4 15.9
    3 18.8 220.3 708.0 663.0 471.5 201.4 35.6 3.5
    4 2.9 124.4 274.5 307.0 224.0 61.4 16.6 5.4
    5 76.1 287.0 413.5 384.5 214.0 105.5 20.8 6.4
    6 20.4 396.0 370.0 211.0 95.9 24.9 9.2 4.8
    Average 33.85 266.98 439.60 381.60 261.28 106.88 22.93 6.38
    Standard 28.18 98.01 190.70 184.77 148.64 70.49 14.60 4.88
    deviation
  • TABLE 3
    Administration of AVICEL PH-F20 (water-soluble insulin)
    (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 3.8 385.0 434.0 392.0 322.0 123.2 18.4 2.3
    2 7.0 72.6 58.6 32.2 28.5 14.0 5.7 6.7
    3 3.4 71.4 98.2 116.3 85.7 29.4 11.3 1.3
    4 3.2 51.2 32.0 18.4 10.8 5.6 3.0 7.9
    5 2.8 228.1 247.0 235.6 171.8 92.4 14.6 4.8
    6 2.7 137.6 108.0 65.7 37.9 19.1 14.0 1.3
    Average 3.82 157.65 162.97 143.37 109.45 47.28 11.17 4.05
    Standard 1.61 128.89 152.17 144.96 119.19 48.49 5.81 2.85
    deviation
  • TABLE 4
    Administration of AVICEL PH-101 (water-insoluble insulin)
    (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 8.2 80.4 63.9 32.0 19.4 8.8 3.4 3.3
    2 5.2 83.0 162.8 125.6 96.2 44.7 9.7 2.7
    3 12.7 159.6 265.0 265.5 211.4 103.0 16.8 5.1
    4 2.7 113.1 182.2 160.3 73.5 41.0 4.8 3.2
    5 4.5 62.6 89.8 40.8 23.8 13.1 5.1 3.3
    6 5.4 184.7 207.7 120.2 56.5 35.7 5.6 5.5
    Average 6.45 113.90 161.90 124.07 80.13 41.05 7.57 3.85
    Standard 3.54 48.60 74.76 85.72 70.65 33.77 5.00 1.15
    deviation
  • TABLE 5
    Administration of AVICEL PH-101 (water-soluble insulin)
    (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 0.4 176.6 172.3 88.0 58.7 32.6 10.9 3.6
    2 2.0 127.9 118.3 73.2 52.3 21.4 4.2 1.4
    3 1.8 123.2 160.2 110.3 109.2 42.7 6.7 0.6
    4 8.6 153.4 151.6 76.2 35.9 16.1 2.0 2.2
    5 6.0 108.8 71.9 69.0 35.5 17.3 5.0 1.9
    6 0.9 196.8 111.5 73.5 38.5 17.6 9.4 7.2
    Average 3.28 147.78 130.97 81.70 55.02 24.62 6.37 2.82
    Standard 3.27 34.01 37.46 15.42 28.20 10.74 3.33 2.37
    deviation
  • Table 1 shows that when 16 IU/head of insulin was nasally administered, the most favorable insulin absorption was seen in the order water-insoluble insulin with Avicel® PH-F20, followed by water-soluble insulin with Avicel® PH-F20, water-insoluble insulin with Avicel® PH-101 (all these are the present invention), water-soluble insulin with Avicel® PH-101 (comparison), and it is clear that the compositions according to the present invention reached significantly high serum insulin concentrations in comparison with the comparative composition.
  • (2) Subsequent examples are of studies conducted with water-insoluble insulin, which show good absorption, using various crystalline aggregate carriers for nasal administration. 35 mg of powdered water-insoluble insulin (28.7 IU/mg), received as described above, and crystalline cellulose [Asahi Chemical Industrial Co., Ltd.: Avicel® PH-101 and Avicel® PH-301, Avicel® PH-F20, and Avicel® PH-M15 (965 mg of each)], were thoroughly mixed in a mortar to prepare nasal administration compositions, and each was administered to cynomolgus monkeys (n=6). Pharmacokinetic parameters calculated from serum insulin concentrations after administration are shown in Table 6 (mean value±SD).
  • Serum insulin and glucose concentration-time curves after nasal administration of compositions described above are shown in FIGS. 3 and 4. Raw data relating to FIG. 3 are shown in Tables 7 to 10.
    TABLE 6
    Kind of Dosage Number of AUC0-4
    preparation (IU/body) animals Cmax (μU/mL) Tmax (h) T1/2 (h) (μU · h/mL)
    AVICEL PH-101 16 6 164.73 ± 70.76 0.33 ± 0.10 0.78 ± 0.26 129.78 ± 78.45
    AVICEL PH-301 16 6 353.57 ± 174.91 0.39 ± 0.14 0.65 ± 0.10 328.13 ± 162.93
    AVICEL PH-F20 16 6 449.35 ± 183.66 0.33 ± 0.10 0.75 ± 0.33 361.55 ± 167.55
    AVICEL PH-M15 16 6 225.40 ±  89.70 0.28 ± 0.08 1.09 ± 0.53 214.57 ± 72.37
  • TABLE 7
    Administration of AVICEL PH-101 (chronological
    change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 8.2 80.4 63.9 32.0 19.4 8.8 3.4 3.3
    2 5.2 83.0 162.8 125.6 96.2 44.7 9.7 2.7
    3 12.7 159.6 265.0 265.5 211.4 103.0 16.8 5.1
    4 2.7 113.1 182.2 160.3 73.5 41.0 4.8 3.2
    5 4.5 62.6 89.8 40.8 23.8 13.1 5.1 3.3
    6 5.4 184.7 207.7 120.2 56.5 35.7 5.6 5.5
    Average 6.45 113.90 161.90 124.07 80.13 41.05 7.57 3.85
    Standard 3.54 48.60 74.76 85.72 70.65 33.77 5.00 1.15
    deviation
  • TABLE 8
    Administration of AVICEL PH-301 (chronological
    change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 9.1 129.7 77.0 41.1 24.2 19.1 1.8 1.5
    2 20.5 447.5 586.0 385.0 241.0 73.8 18.6 5.3
    3 9.4 185.9 239.0 367.5 313.5 225.7 77.6 4.2
    4 22.7 263.0 387.0 397.5 293.5 203.3 40.0 11.6
    5 10.9 419.0 469.5 326.5 234.8 119.2 24.9 7.1
    6 7.4 141.2 167.6 171.2 122.4 79.2 19.9 3.8
    Average 13.33 264.38 321.02 281.47 204.90 120.05 30.47 5.58
    Standard 6.54 139.22 193.09 143.91 110.72 80.11 26.14 3.47
    deviation
  • TABLE 9
    Administration of AVICEL PH-F20 (chronological
    change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 60.8 225.2 239.6 194.6 149.8 66.9 10.0 2.3
    2 24.1 349.0 632.0 529.5 412.5 181.2 45.4 15.9
    3 18.8 220.3 708.0 663.0 471.5 201.4 35.6 3.5
    4 2.9 124.4 274.5 307.0 224.0 61.4 16.6 5.4
    5 76.1 287.0 413.5 384.5 214.0 105.5 20.8 6.4
    6 20.4 396.0 370.0 211.0 95.9 24.9 9.2 4.8
    Average 33.85 266.98 439.60 381.60 261.28 106.88 22.93 6.38
    Standard 28.18 98.01 190.70 184.77 148.64 70.49 14.60 4.88
    deviation
  • TABLE 10
    Administration of AVICEL PH-M15 (chronological
    change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 18.0 264.0 223.9 125.0 69.2 37.5 11.8 6.6
    2 10.2 309.5 348.0 289.0 202.1 126.5 26.8 8.9
    3 6.6 158.9 194.4 179.1 145.5 102.2 25.4 7.2
    4 23.6 118.5 140.1 94.5 60.3 67.6 40.0 22.8
    5 19.1 288.0 277.0 136.0 71.9 38.2 14.2 17.2
    6 24.9 89.5 117.9 105.6 55.6 26.3 17.8 19.0
    Average 17.07 204.73 216.88 154.87 100.77 66.38 22.67 13.62
    Standard 7.29 94.06 86.09 71.97 59.63 40.33 10.38 6.91
    deviation
  • Table 6 shows that when 16 IU/head of insulin was nasally administered, the most favorable insulin absorption was seen in the order Avicel® PH-F20, followed by Avicel® 301, Avicel® PH-M15, and Avicel® PH-101 in that order, and it is clear that the compositions according to the present invention reached significantly high serum insulin concentrations in comparison with the comparative composition. AUC0-4 (μU·h/mL) of Avicel® PH-F20 was about three times that of Avicel® PH-101 (see FIG. 3). Avicel® PH-101 and Avicel® PH-F20 were produced serially; Avicel® PH-101 being chopped and pulverized to form Avicel® PH-F20. The method of producing Avicel® 301 and Avicel® PH-M15 was different from that of Avicel® PH-101. Avicel® PH-F20, Avicel® 301, Avicel® PH-M15, and Avicel® PH-101 have bulk densities of 0.23, 0.39, 0.53, and 0.29 g/cm3, respectively.
  • (3) Avicel® PH-F20 derivatives were classified into particle diameters (see Table 11 for sieve distribution), of 20-25 μm (hereafter F-20 20-25 μm), 25-38 μm (hereafter F-20 25-38 μm), 38-53 μm (hereafter F-20 38-53 μm), 25-53 μm (hereafter F-20 25-53 μm), 53 μm or below (hereafter F-20 53 μm or below), and 53 μm or above (hereafter F-20 53 μm or above) and nasally admi1nistered to cynomolgus monkeys as carriers, prepared in the proportions described above, for water-insoluble insulin (16 IU/head) and serum insulin and glucose concentrations were measured. Pharmacokinetic parameters calculated from serum insulin concentrations after administration are shown in Table 12 (mean value±SD).
    TABLE 11
    Sieve-through
    particle diameter Sieve-through Sieve-through
    (μm) amount (g) rate (%)
    20-25 1.98 6.6
    25-38 12.35 41.2
    38-53 13.20 44.0
    53 or more 2.14 7.1
    Total 29.67 98.9
    (Loss amount: 0.33 g) (Loss rate: 1.1%)
  • TABLE 12
    Kind of Dosage Number AUC0-4
    preparation (IU/body) of animals Cmax (μU/mL) Tmax (h) T1/2 (h) (μU · h/mL)
    F20 16 6 449.35 ± 183.66 0.33 ± 0.10 0.75 ± 0.33 361.55 ± 167.55
    F20 20-25 μm 16 6 191.95 ± 51.11 0.25 ± 0.09 0.74 ± 0.11 156.33 ± 62.74
    F20 25-38 μm 16 6 291.45 ± 113.75 0.22 ± 0.08 0.91 ± 0.31 227.75 ± 168.21
    F20 38-53 μm 16 6 364.82 ± 209.04 0.22 ± 0.08 0.62 ± 0.11 256.89 ± 167.69
    F20 25-53 μm 16 6 232.90 ± 118.64 0.31 ± 0.12 0.93 ± 0.36 203.69 ± 128.28
    F20 53 μm or less 16 6 280.20 ± 164.68 0.25 ± 0.09 1.23 ± 0.69 218.81 ± 153.03
    F20 53 μm or more 16 6 194.68 ± 93.39 0.28 ± 0.08 1.01 ± 0.51 169.61 ± 78.58
  • Serum insulin and glucose concentration-time curves after nasal administration of preparations described above are shown in FIGS. 5 and 6. Raw data relating to FIG. 5 are shown in Tables 13-19.
    TABLE 13
    Administration of F20 (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 60.8 225.2 239.6 194.6 149.8 66.9 10.0 2.3
    2 24.1 349.0 632.0 529.5 412.5 181.2 45.4 15.9
    3 18.8 220.3 708.0 663.0 471.5 201.4 35.6 3.5
    4 2.9 124.4 274.5 307.0 224.0 61.4 16.6 5.4
    5 76.1 287.0 413.5 384.5 214.0 105.5 20.8 6.4
    6 20.4 396.0 370.0 211.0 95.9 24.9 9.2 4.8
    Average 33.85 266.98 439.60 381.60 261.28 106.88 22.93 6.38
    Standard 28.18 98.01 190.70 184.77 148.64 70.49 14.60 4.88
    deviation
  • TABLE 14
    Administration of F20 20-25 μm (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 24.4 184.1 160.1 91.9 60.1 28.2 5.0 7.0
    2 13.1 271.5 230.3 198.6 128.7 66.1 20.7 3.4
    3 17.6 209.4 223.6 190.4 144.0 71.7 31.2 7.7
    4 5.9 120.2 111.6 90.6 61.5 46.4 6.2 2.4
    5 10.4 152.4 173.0 88.6 48.9 12.9 4.4 3.6
    6 13.8 152.4 179.3 119.1 65.8 35.5 5.8 4.5
    Average 14.20 181.67 179.65 129.87 84.83 43.47 12.22 4.77
    Standard 6.33 53.55 43.71 51.36 40.58 22.58 11.16 2.12
    deviation
  • TABLE 15
    Administration of F20 25-38 μm (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 13.4 217.7 185.0 102.3 66.3 59.6 10.7 9.5
    2 44.1 181.5 334.0 221.9 145.6 67.4 16.0 9.0
    3 14.0 341.0 500.0 449.0 368.0 196.2 74.9 6.3
    4 13.3 216.9 125.2 53.6 39.4 17.6 9.5 8.1
    5 8.3 200.6 152.6 79.9 54.1 21.3 7.4 6.2
    6 2.6 279.5 171.8 73.9 47.2 26.3 32.3 6.4
    Average 15.95 239.53 244.77 163.43 120.10 64.73 25.13 7.58
    Standard 14.47 59.61 144.77 152.16 127.42 67.68 25.99 1.48
    deviation
  • TABLE 16
    Administration of F20 38-53 μm (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 6.9 237.5 193.6 112.1 62.5 33.9 12.7 1.4
    2 10.4 508.5 633.0 440.5 414.0 114.8 16.0 4.1
    3 8.3 419.5 604.5 484.5 336.5 83.9 16.9 2.4
    4 45.3 351.0 333.5 305.5 180.7 100.5 17.4 2.9
    5 9.0 233.8 204.5 68.7 32.4 12.4 2.6 3.5
    6 9.7 129.1 96.1 54.3 38.9 16.0 4.9 4.8
    Average 14.93 313.23 344.25 244.27 177.50 60.25 11.75 3.18
    Standard 14.93 139.14 225.81 192.01 164.14 44.94 6.45 1.22
    deviation
  • TABLE 17
    Administration of F20 25-53 μm (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 39.3 140.5 80.2 41.7 23.5 10.0 Hemolysis 4.1
    2 7.1 82.1 120.8 58.4 38.7 14.8 3.7 6.2
    3 5.8 102.5 235.8 269.0 197.4 116.9 31.7 6.8
    4 40.0 181.5 389.0 337.0 262.0 111.0 22.3 12.0
    5 7.0 247.0 347.5 286.5 207.9 127.6 27.3 7.8
    6 9.2 130.6 124.6 80.3 48.8 34.6 12.0 5.0
    Average 18.07 147.37 216.32 178.82 129.72 69.15 19.40 6.98
    Standard 16.76 59.49 129.21 132.48 104.22 54.94 11.44 2.78
    deviation
  • TABLE 18
    Administration of F20 53 μm or less (chronological
    change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 30.7 285.5 242.0 154.7 88.9 51.0 7.5 5.4
    2 11.3 348.5 342.0 220.6 135.0 34.6 17.8 8.4
    3 3.7 330.0 464.5 367.5 287.5 125.0 81.1 10.7
    4 12.3 76.4 83.6 50.8 28.0 14.8 7.5 14.1
    5 18.8 81.6 56.9 17.5 18.0 16.6 6.8 6.8
    6 23.9 373.5 417.5 278.0 127.3 45.6 7.2 5.8
    Average 16.78 249.25 267.75 181.52 114.12 47.93 21.32 8.53
    Standard 9.69 134.99 170.69 134.26 97.94 40.59 29.59 3.35
    deviation
  • TABLE 19
    Administration of F20 53 μm or more (chronological
    change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 10 min 20 min 30 min 40 min 1 hr 2 hrs 4 hrs
    1 6.6 84.2 90.5 61.5 44.5 17.3 11.2 6.0
    2 4.6 273.5 334.5 147.5 99.7 49.4 8.4 7.9
    3 1.6 130.8 221.1 195.3 202.3 176.2 19.3 7.4
    4 13.6 129.8 133.4 77.2 78.8 35.5 11.3 10.1
    5 10.5 260.5 225.0 147.6 120.1 55.6 10.6 4.5
    6 3.8 119.1 131.7 71.8 26.1 27.4 8.3 9.2
    Average 6.78 166.32 191.03 116.82 100.25 60.23 11.52 7.52
    Standard 4.49 79.91 95.11 54.32 57.14 58.52 4.04 2.05
    deviation
  • Table 12 shows that when 16 IU/head of insulin was nasally administered, insulin absorption with unclassified F-20 particles and aggregated crystalline cellulose preparations with a particle distribution across a partial region of the diameter range was slightly lower than the maximum serum insulin concentration of F-20; however, it was significantly higher than that of the comparative composition. As a reference, the raw data of intravenous administration of insulin injection solution are shown in Table 20.
    TABLE 20
    Intravenous administration (chronological change in insulin concentration)
    Animal Insulin (μU/mL)
    No. 0 2 min 5 min 10 min 15 min 30 min 1 hr 2 hrs
    1 9.7 1489.0 671.0 224.6 76.1 19.0 5.5 1.3
    2 4.8 1626.0 482.0 378.0 231.5 64.2 6.7 0.8
    3 10.0 1330.0 947.0 454.0 285.5 86.5 14.2 1.5
    4 22.3 982.5 391.5 265.0 150.1 43.2 6.6 2.1
    5 20.4 1039.0 525.0 235.5 107.2 19.9 5.3 2.3
    Average 13.44 1293.30 603.30 311.42 170.08 46.56 7.66 1.60
    Standard 7.54 279.11 217.04 100.27 87.01 29.10 3.71 0.61
    deviation

    Pharmacokinetic and Pharmacological Trials in Humans
  • A composition with Avicel® PH-F20 as the carrier was nasally administered once and serum insulin and glucose concentrations were measured chronologically.
  • Insulin and glucose concentrations were measured by Enzyme Immune Assay (EIA) and Glck•G-6-PDH, respectively.
  • Each pharmaceutical preparation was placed in a capsule, and administered intranasally with an administration device (Jetlizer, Unisia Jecs Corporation).
  • 35 mg of powdered water-insoluble insulin (28.7 IU/mg), was thoroughly mixed in a mortar with 965 mg of Avicel® PH-F20 (hereafter F-20) and nasally administered to three healthy adult males. Pharmacokinetic parameters calculated from serum insulin concentrations after administration are shown in Table 21 (mean value±SD). Serum insulin and glucose concentration-time curves after nasal administration of compositions described above are shown in FIGS. 7 and 8. Raw data relating to FIG. 7 are shown in Table 22.
    TABLE 21
    Kind of Dosage Number of AUC0-2
    composition (IU/body) examinee Cmax (μU/mL) Tmax (h) T1/2 (h) (μU · h/mL)
    F20 16 3 21.80 ± 0.85 0.28 ± 0.09 1.34 ± 0.73 25.28 ± 5.88
  • TABLE 22
    Administration of F20 (chronological change in insulin concentration)
    Examinee Insulin (μU/mL)
    No. 0 10 min 20 min 40 min 1 hr 1.5 hrs 2 hrs
    1 7.9 17.5 20.9 14.9 11.8 10.4 10.4
    2 16.6 21.9 20.8 19.8 14.0 8.7 13.8
    3 5.1 13.8 22.6 15.2 7.4 3.5 2.5
    Average 9.87 17.73 21.43 16.63 11.07 7.53 8.90
    Standard 6.00 4.06 1.01 2.75 3.36 3.59 5.80
    deviation
  • Table 21 shows that granulated compositions related to the present invention show favorable serum insulin concentrations and are excellent nasal administration agents (refer to FIGS. 7 and 8).
    • Industrial Applicability
  • Granulated compositions relating to the present invention when nasally administered to mammals, including human beings, readily and efficiently increase blood insulin concentrations. Accordingly, the present invention can be utilized by pharmaceutical producers that provide such compositions as well as by other medical industries.

Claims (4)

1-5. (canceled)
6. A granulated composition for nasal administration composed of powdered insulin and its carrier, aggregated crystalline cellulose, the distinguishing features of which are that the said insulin is soluble, and that 85 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 20-60 μm in one part or across the whole area, and the said granulated composition has a particle diameter falling substantially within the range of that prescribed for the said crystalline cellulose aggregate.
7. The composition as described in claim 6 having a cribriform particle diameter range distributions of:
w/w % or less of particle diameters below 25 μm,
20-60 w/w % of particle diameters of 25-38 μm,
20-60 w/w % of particle diameters greater than 38 μm and up to 53 μm, and
10 w/w % or less of particle diameters exceeding 53 μm, taking the entire particle as 100%.
8-14. (canceled)
US11/078,292 2001-07-05 2005-03-14 Composition of insulin for nasal administration Abandoned US20050158250A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/078,292 US20050158250A1 (en) 2001-07-05 2005-03-14 Composition of insulin for nasal administration

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001204784 2001-07-05
JP2001-204784 2001-07-05
PCT/JP2002/006721 WO2003004048A1 (en) 2001-07-05 2002-07-03 Compositions for nasal administration of insulin
US10/250,862 US6906027B2 (en) 2001-07-05 2002-07-03 Composition for nasal administration of insulin
US11/078,292 US20050158250A1 (en) 2001-07-05 2005-03-14 Composition of insulin for nasal administration

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/250,862 Continuation US6906027B2 (en) 2001-07-05 2002-07-03 Composition for nasal administration of insulin
PCT/JP2002/006721 Continuation WO2003004048A1 (en) 2001-07-05 2002-07-03 Compositions for nasal administration of insulin

Publications (1)

Publication Number Publication Date
US20050158250A1 true US20050158250A1 (en) 2005-07-21

Family

ID=19041200

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/250,862 Expired - Fee Related US6906027B2 (en) 2001-07-05 2002-07-03 Composition for nasal administration of insulin
US11/078,292 Abandoned US20050158250A1 (en) 2001-07-05 2005-03-14 Composition of insulin for nasal administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/250,862 Expired - Fee Related US6906027B2 (en) 2001-07-05 2002-07-03 Composition for nasal administration of insulin

Country Status (11)

Country Link
US (2) US6906027B2 (en)
EP (1) EP1413311A4 (en)
JP (1) JP4721212B2 (en)
KR (1) KR20030027108A (en)
CN (1) CN100341567C (en)
AU (1) AU2002346143B2 (en)
CA (1) CA2433583A1 (en)
HK (1) HK1064953A1 (en)
MX (1) MXPA03005980A (en)
RU (1) RU2299743C2 (en)
WO (1) WO2003004048A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US9138410B2 (en) 2003-02-21 2015-09-22 Shin Nippon Biomedical Laboratories, Ltd. Compositions for nasal administration of pharmaceuticals
US20160228433A1 (en) * 2013-09-24 2016-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
US10195139B2 (en) * 2006-12-26 2019-02-05 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
US10758532B2 (en) 2018-12-11 2020-09-01 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906027B2 (en) * 2001-07-05 2005-06-14 Translational Research Ltd. Composition for nasal administration of insulin
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
EP1785145A4 (en) * 2004-08-10 2008-08-13 Translational Res Ltd Transnasal composition having immediate action and high absorbability
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
UA90013C2 (en) 2008-03-19 2010-03-25 Давид Анатолійович Нога Pharmaceutical composition containing insulin and process for the preparation thereof
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
HUE050050T2 (en) 2013-03-04 2020-11-30 Besins Healthcare Lu Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
WO2019130701A1 (en) * 2017-12-26 2019-07-04 旭化成株式会社 Cellulose powder
JPWO2020230676A1 (en) * 2019-05-16 2020-11-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906027B2 (en) * 2001-07-05 2005-06-14 Translational Research Ltd. Composition for nasal administration of insulin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59163313A (en) 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
JPS60224616A (en) 1984-04-24 1985-11-09 Teijin Ltd Composition for administration through nose
JPS6242888A (en) 1985-08-21 1987-02-24 カシオ計算機株式会社 Integrated circuit card with solar cell
JP2505430B2 (en) 1986-11-04 1996-06-12 帝人株式会社 Powdery composition for nasal administration containing basic amino acid
JPH0715963B2 (en) 1987-08-31 1995-02-22 松下電器産業株式会社 Semiconductor device
JP2802488B2 (en) * 1995-02-08 1998-09-24 有限会社ドット Bioactive peptide composition for nasal absorption
JP3197221B2 (en) 1996-02-27 2001-08-13 帝人株式会社 Powdery nasal composition having improved absorption
KR100568436B1 (en) * 1996-02-27 2007-04-25 데이진 가부시키가이샤 Powdery composition for nasal administration
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
CN1160127C (en) * 1998-08-26 2004-08-04 帝人株式会社 Powdery pernasal compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906027B2 (en) * 2001-07-05 2005-06-14 Translational Research Ltd. Composition for nasal administration of insulin

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138410B2 (en) 2003-02-21 2015-09-22 Shin Nippon Biomedical Laboratories, Ltd. Compositions for nasal administration of pharmaceuticals
US10195139B2 (en) * 2006-12-26 2019-02-05 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US20160228433A1 (en) * 2013-09-24 2016-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US12102754B2 (en) 2017-09-26 2024-10-01 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US10758532B2 (en) 2018-12-11 2020-09-01 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches

Also Published As

Publication number Publication date
US6906027B2 (en) 2005-06-14
US20040063615A1 (en) 2004-04-01
CN100341567C (en) 2007-10-10
JP4721212B2 (en) 2011-07-13
EP1413311A4 (en) 2005-10-19
WO2003004048A1 (en) 2003-01-16
JPWO2003004048A1 (en) 2005-11-24
MXPA03005980A (en) 2003-09-10
RU2004103187A (en) 2005-06-10
CN1491114A (en) 2004-04-21
EP1413311A1 (en) 2004-04-28
AU2002346143B2 (en) 2007-10-04
RU2299743C2 (en) 2007-05-27
CA2433583A1 (en) 2003-01-16
KR20030027108A (en) 2003-04-03
HK1064953A1 (en) 2005-02-08

Similar Documents

Publication Publication Date Title
US20050158250A1 (en) Composition of insulin for nasal administration
US9138410B2 (en) Compositions for nasal administration of pharmaceuticals
US20230302093A1 (en) Nasal powder formulation for treatment of hypoglycemia
JP3634380B2 (en) Powdered nasal administration composition
TWI301761B (en) Zinc-free and low-zinc insulin preparations having improved stability
JP2548056B2 (en) Preparation for suppressing and preventing autoimmune disease related to type I diabetes
RO121834B1 (en) Device for the delivery of an active agent
US7662403B2 (en) Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof
EP0648498A1 (en) Physiologically active peptide compositions
HU218940B (en) Therapeutic preparation for inhalation containing parathyroid hormone (pth), process for producing them, use for respirator filling, and respirator containing them
EP1036562A1 (en) Soft-pellet drug and process for the preparation thereof
D’Souza et al. Nasal insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies
RU2592983C2 (en) Combined therapy including vemurafenib and interferon, for use in treating cancer
CN113018277B (en) Sustained release preparation for injection and preparation method thereof
CA2106038A1 (en) Physiologically active peptide composition
JP4212019B2 (en) Composition for nasal administration of a drug
JP2007161702A (en) Pharmaceutical composition for aqueous inhalation
CN114949183B (en) Tinepotide powder aerosol and preparation method thereof
EP1790351A1 (en) Permucosal composition and method of improving permucosal absorption
CZ20022151A3 (en) Method for reducing rate of increase in body weight and decrease of sugar level in blood due to hunger in diabetic patients
CN110063932A (en) A kind of slow releasing composition preparation of polypeptide protein class drug and preparation method thereof
CN1966072A (en) Orally administered enteric-coated composition of calcitonin and preparation method thereof
WO2023212033A9 (en) Extended-release formulation containing cresol
CN106727448A (en) Octreotide acetate dry powder inhaler formulations and preparation method thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION